# US 2016/0250295 A1 · Formulation for gonadotropins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250295 A1
- Document ID: US20160250295A1
- Status: Published application
- Kind: A1
- Application number: 15/030,527
- Filed: 2014-10-31
- Published: 2016-09-01
- Earliest claimed: 2013-11-12
- Assignees: Cadila Healthcare Limited
- Applicants: Cadila Healthcare Limited
- Inventors: Chintan PATEL; Mukesh MAHAJAN; Sanjay BANDYOPADHYAY; Sanjee Kumar MENDIRATTA; Bhatt CHANDRESH
- Web page: https://patentgrep.com/patent/US20160250295A1

## CPC

- A61K 38/24: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 5/24: of the sex hormones
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a stable composition for gonadotropins. It provides a composition useful for stabilization of gonadotropins while preventing aggregation, dissociation, fragmentation and formation of oxidized species variants in solution for injection. Thus, it prevents instability of protein or polypeptide molecules caused due to aggregation or fragmentation or oxidation during or after formulation. Also, it provides a pharmaceutical composition of gonadotropins, which can be therapeutically used for the treatment of various indications either in single-dose form or in multi-dose form.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A liquid pharmaceutical formulation comprising an effective amount of gonadotropin in a buffer system, polyethylene glycol as a stabilizer, suitable preservative and optionally other suitable excipients.

### Claim 30 (depends on 29)

The formulation as claimed in claim 29, wherein the buffer system is selected from histidine-buffer, arginine-buffer, citrate-buffer, succinate-buffer acetate-buffer, phosphate-buffer, tromethamine buffers, or citrate-phosphate buffer or a mixture thereof, wherein the buffer is in a concentration of 5 mM to about 100 mM.

### Claim 31 (depends on 29)

The formulation as claimed in claim 29, wherein the polyethylene glycol is present in the concentration of 0.005% to 10%.

### Claim 32 (depends on 29)

The formulation as claimed in claim 29, wherein the preservative is selected from hydroxybenzenes (phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol and the like), paraben (methyl, ethyl, propyl, butyl and the like), sodium benzoate, benzyl benzoate, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal or mixtures thereof preferably, sodium benzoate or phenol wherein the preservative is present in a concentration of 0.01% to 1%.

### Claim 33 (depends on 29)

The formulation as claimed in claim 29, wherein other suitable excipients can be selected from antioxidants, other stabilizers, surfactants, tonicity agents and suitable combination thereof.

### Claim 34 (depends on 33)

The formulation as claimed in claim 33, wherein the antioxidant is selected from EDTA, ascorbic acid or a combination thereof, wherein the antioxidant is present in the concentration of 0.001% to 1.

### Claim 35 (depends on 33)

The formulation ax claimed in claim 33, wherein the surfactant is selected from polyoxyethylensorbitan fatty acid esters (Tween), polyoxyethylene alkyl ethers, alkylphenylpolyoxyethylene ethers, polyoxyethylene-polyoxypropylene copolymer and sodium dodecyl sulphate (SDS), preferably polysorbate 80 or polyoxyethylene-polyoxypropylene copolymer, wherein the surfactant is present in the concentration of 0.001% to about 1%.

### Claim 36 (depends on 33)

The formulation as claimed in claim 33, wherein the tonicity agent is sodium chloride or potassium chloride wherein the tonicity agent is present in amount about 10 mM to about 150 mM.

### Claim 37 (depends on 33)

The formulation as claimed in claim 33, wherein the stabilizer is selected from suitable sugars, polyols, amino acids or a combination thereof.

### Claim 38 (depends on 37)

The formulation as claimed in claim 37, wherein the amino acid is selected from arginine, glycine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline, cysteine/cystine and suitable combination thereof wherein the amino acid is present in the concentration of 0.01% to 1%.

### Claim 39 (depends on 37)

The formulation as claimed in claim 37, wherein the sugar is selected from glucose, fructose, galactose, mannose, sorbose, ribose, deoxyribose, dextran, dextrin, sucrose, trehalose, lactose, maltose, raffinose and suitable mixtures thereof, wherein the sugar is present in the concentration of 0.005% to 10%.

### Claim 40 (depends on 29)

The formulation as claimed in claim 29, wherein the concentration of gonadotropin is between 5 μg/ml to 200 μg/ml or wherein the pH of the formulation is between pH 6 and pH 8.

### Claim 41 (depends on 29)

A formulation as claimed in claim 29, comprising:
a) 5-200 μg/ml of gonadotropin;
b) 0.005-10% polyethylene glycol;
c) a buffer system for maintaining the pH between 6 and 8;
d) 0.01-1% of preservative; and
e) optionally with other suitable excipients.

### Claim 42 (depends on 41)

The formulation as claimed in claim 41, wherein the buffer system is a phosphate of succinate or acetate or citrate-phosphate buffer system and the preservative is sodium benzoate or phenol or m-cresol.

### Claim 43 (depends on 41)

The formulation as claimed in claim 41, which further comprises a surfactant and/or tonicity agent selected from polysorbate 80 and/or sodium chloride respectively.

### Claim 44 (depends on 29)

The formulation as claimed in claim 29, wherein the gonadotropin is selected from follicle stimulating hormone or variant thereof luteinizing hormone or variant thereof, human chorionic gonadotropin hormone or variant thereof and combination thereof.

### Claim 45 (depends on 44)

The formulation as claimed in claim 44, wherein the follicle stimulating hormone is follitropin alfa or Follitropin beta or both.

### Claim 46 (depends on 41)

The formulation as claimed in claim 41, further comprises antioxidant selected from EDTA, ascorbic acid and combination thereof.

### Claim 47 (depends on 29)

A formulation as claimed in claim 29, comprising:
a) 44 μg/ml of follitropin alfa;
b) 0.1% polyethylene glycol;
c) 10 mM phosphate butler with a pH about 7;
d) 0.1% of EDTA;
e) 0.3% of sodium benzoate; and
f) 100 mM of sodium chloride.
